Table 1 Baseline characteristics of patients with RA in the TSUBAME study
Variables | n = 100 |
|---|---|
Age (y) | 58 (48–68) |
Gender, n (% female) | 82 (82.0%) |
Disease duration (mo) | 29 (8–84) |
Stage (I/II/III/IV %) | 40/48/6/6 |
Treatment history | |
MTX use at baseline, n (%) | 100 (100%) |
Dose, mg/w | 14 (10–16) |
Glucocorticoid use at baseline, n (%) | 8 (8%) |
Dose, mg/day | 4.5 (2.0–7.0) |
bDMARDS naïve, n (%) | 73 (73%) |
Prior use of TNFi | 18 (18%) |
Prior use of Non-TNFi | 6 (6%) |
Prior use of both TNFi and non-TNFi | 3 (3%) |
28-tender joint count | 8 (4–13) |
28-swollen joint count | 7 (3–11) |
GH, VAS 0-100 mm | 48 (26–70) |
EGA, VAS 0-100 mm | 40 (28–60) |
Pain, VAS 0-100 mm | 52 (28–72) |
DAS28-ESR | 5.4 ± 1.3 |
HAQ-DI | 1 (0.5–1.5) |
EQ-5D | 0.6 (0.5–0.7) |
CRP (mg/dl) | 0.6 (0.1–2.1) |
ESR (mm/h) | 37 (21–68) |
Rheumatoid factor (U/ml) | 56.4 (21.1–129.1) |
Anti-CCP antibody (U/ml) | 95.0 (24.7–384.5) |
MMP-3 (ng/ml) | 87.3 (34.5–328) |